Agmatine sulfate
Agmatine Sulfate · also known as Agmatine, Agmatine, Super arginine, Endogenous neuromodulator
Agmatine is made from L-arginine by arginine decarboxylase. Animal and in-vitro (cell) studies suggest it can act on NMDA receptors, imidazoline receptors and nitric oxide synthase. Its oral absorption in humans, its brain exposure and the strength of its target effects are not established, so it cannot yet be treated as a proven neuroprotective agent.
Clinical uses and human evidence
Peripheral neuropathy (numbness and tingling)
Mechanisms of action
Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)
In rats, injected agmatine altered the firing of 5-HT neurons in the dorsal raphe nucleus and the expression of related receptors. But injection differs from oral supplementation, and effects at α2 and imidazoline receptors cannot be directly equated with regulation of monoamine synthesis or transport. Human effects are unknown.
GABA and glutamate balance (inhibitory and excitatory tone)
In-vitro binding experiments suggest agmatine acts on polyamine-related sites of the NMDA receptor, opposing spermine-like enhancement. Blocking the channel directly requires higher concentrations, and there are no measurements of NMDA receptor occupancy in the human brain at usual oral doses.
References (2)
- Gibson et al. 2002 · In-vitro binding experiment in rat brain membranes: agmatine opposed spermine-like enhancement at NMDA receptor polyamine sites; direct inhibition of labeled binding required higher concentrations
- No direct study found in literature search · Conclusion: no reliable measurement of NMDA receptor occupancy or channel block in the human brain at usual oral doses
Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation
In isolated aorta experiments, agmatine affected eNOS phosphorylation, cGMP and relaxation responses, and brain eNOS expression changed in a rat ischemia model. However, these results do not establish endothelial coupling or vasodilation after oral intake, so “selective activation of eNOS” currently lacks support.
Safety and drug interactions
With Levodopa Needs attention
May affect the action of dopaminergic drugs. Do not combine them without medical guidance.